Leinco Technologies

Anti-ACE2 (Intermediate Domain)

Product Code:
 
LEI-A315
Product Group:
 
Primary Antibodies
Host Type:
 
Rabbit
Antibody Isotype:
 
IgG
Antibody Clonality:
 
Polyclonal
Regulatory Status:
 
RUO
Target Species:
  • Human
  • Mouse
  • Rat
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunofluorescence (IF)
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
  • Western Blot (WB)
Shipping:
 
Ambient
Storage:
 
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-A315-20ug20 ug£199.00
Quantity:
LEI-A315-0.1mg0.1 mg£591.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
ACE2 antibody was raised against a synthetic peptide corresponding to amino acids near the center of human ACE2. The immunogen is located within amino acids 150 - 200 of ACE2.
Long Description:
Angiotensin I converting enzyme 2 (ACE2) is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin, or the conversion of angiotensin II to angiotensin. ACE 2 has direct effects on cardiac function, and is expressed predominantly in vascular endothelial cells of the heart and the kidneys. ACE2 plays a regulatory role in lung pathophysiology, including pulmonary fibrosis and acute lung disease. Activation of ACE2 by a small molecule can be a therapeutically relevant approach for treating and controlling Pulmonary Hypertension (PH). ACE2 may also have clinical potential as a novel molecular target for the treatment of pancreatic ductal adenocarcinoma (PDAC).
Target:
ACE2

References

1. Acton, S. et al. (2000) Circ Res. 87: E1 2. Gamliel-Lazarovich, A. et al. (2007) Cardiovasc Res. 73: 463 3. Nabel, EG. et al. (2000) N Engl J Med. 347: 1795 4. Raizada, MK. et al. (2009) Am J Respir Crit Care Med. 179(11):1048-54. 5. Yuan, Y. et al. (2009) Tohoku J Exp Med. 217: 123